USE OF CROSS-SPECIES ANTI-LATENT TGF-ß1 ANTIBODIES AND METHODS OF USE

PROBLEM TO BE SOLVED: To provide methods of using cross-species anti-latent TGF- beta 1 antibodies to inhibit protease-mediated activation of latent TGF- beta 1 without inhibiting integrin-mediated activation of latent TGF- beta 1, in the treatment of fibrosis and cancer.SOLUTION: Provided is a pharmaceutical formulation for use in the treatment of fibrosis or cancer, comprising an anti-latent TGF- beta 1 antibody of a specific sequence and a pharmaceutically acceptable carrier. Preferably, the anti-latent TGF- beta 1 antibody comprises a modified IgG1 Fc region having reduced effector function compared with a wild type IgG1 Fc region. The anti-latent TGF- beta 1 antibody is preferably used in combination with an immune checkpoint inhibitor such as an anti-PD-1 antibody or an anti-PD-L1 antibody.SELECTED DRAWING: None